Compare Abeona Therapeutics Inc (ABEO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Direxion Daily TSLA Bull 2X Shares trades at $12.29. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| ABEO | TSLL | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $23.03 |
52-Week Low | $4.17 | $10.09 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TSLL trades at $13.95, up 13.41% in the last 24 hours, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Support levels are established at $13 and $12, with resistance near $15. Recent news highlights continued investor interest in leveraged ETF strategies tied to high-growth sectors like Tesla.
The outlook for TSLL is cautiously optimistic, driven by strong technical momentum and sector interest, but risks include market volatility and dependency on underlying asset performance. Investors should weigh the potential for amplified returns against the inherent leverage risks in the ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
